Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB

Open access

Abstract

Mycobacterium tuberculosis is a major human pathogen and the causative agent for the pulmonary disease, tuberculosis (TB). Current treatment programs to combat TB are under threat due to the emergence of multi-drug and extensively-drug resistant TB. Through the use of high throughput whole cell screening of an extensive compound library a number of imidazo[1,2-a]pyridine (IP) compounds were obtained as potent lead molecules active against M. tuberculosis and Mycobacterium bovis BCG. The IP inhibitors (1-4) demonstrated minimum inhibitory concentrations (MICs) in the range of 0.03 to 5 µM against a panel of M. tuberculosis strains. M. bovis BCG spontaneous resistant mutants were generated against IP 1, 3, and 4 at 5× MIC and subsequent whole genome sequencing identified a single nucleotide polymorphism (937)ACC>(937)GCC (T313A) in qcrB, which encodes the b subunit of the electron transport ubiquinol cytochrome C reductase. This mutation also conferred cross-resistance against IP 1, 3 and 4 demonstrating a common target. Gene dosage experiments confirmed M. bovis BCG QcrB as the target where over-expression in M. bovis BCG led to an increase in MIC from 0.5 to >8 µM for IP 3. An acute murine model of TB infection established bacteriostatic activity of the IP series, which await further detailed characterization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0052951

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Compounds from the IP series active against M. tuberculosis. Structures of the initial IP hits (1 and 2) identified in the HTS campaign against M. bovis BCG (activity later confirmed in M. tuberculosis) and of optimized compounds 3 and 4.
Figure 1 Compounds from the IP series active against M. tuberculosis. Structures of the initial IP hits (1 and 2) identified in the HTS campaign against M. bovis BCG (activity later confirmed in M. tuberculosis) and of optimized compounds 3 and 4.CC BY · PubMed Central
Figure 2 Whole blood pharmacokinetic profile and main parameters of IP 3 after oral administration of a 50 mg/kg suspension in 1% aqueous methylcellulose. Main pharmacokinetic parameters were established after non-compartmental analysis: Cmax (maximum concentration observed in whole blood), 3.4 µg/ml; AUC (Area Under the Curve) (0–8 hours), 4.36 µg.h/ml; F (percentage bioavailability), 61%.
Figure 2 Whole blood pharmacokinetic profile and main parameters of IP 3 after oral administration of a 50 mg/kg suspension in 1% aqueous methylcellulose. Main pharmacokinetic parameters were established after non-compartmental analysis: Cmax (maximum concentration observed in whole blood), 3.4 µg/ml; AUC (Area Under the Curve) (0–8 hours), 4.36 µg.h/ml; F (percentage bioavailability), 61%.CC BY · PubMed Central
Figure 3 Therapeutic efficacy of anti-tubercular IP 3 against M. tuberculosis H37Rv in vivo. B6 mice were infected by intra-tracheal instillation with 105 cfu M. tuberculosis H37Rv per mouse. The mice were treated with the anti-tubercular orally once a day from day 1 to day 8. Efficacy results are expressed as log cfu reduction in the lungs of infected mice and are the mean±SD of five mice. The shaded line indicates the levels of administered mycobacterial inoculum.
Figure 3 Therapeutic efficacy of anti-tubercular IP 3 against M. tuberculosis H37Rv in vivo. B6 mice were infected by intra-tracheal instillation with 105 cfu M. tuberculosis H37Rv per mouse. The mice were treated with the anti-tubercular orally once a day from day 1 to day 8. Efficacy results are expressed as log cfu reduction in the lungs of infected mice and are the mean±SD of five mice. The shaded line indicates the levels of administered mycobacterial inoculum.CC BY · PubMed Central
Figure 4 Cross-resistance of M. bovis BCG mutants resistant to IP compounds. M. bovis BCG resistant mutants raised against IP 1, 3 and 4 were plated at 5× MIC of each of the respective compounds. A wild-type control demonstrates the resistant nature of the mutants.
Figure 4 Cross-resistance of M. bovis BCG mutants resistant to IP compounds. M. bovis BCG resistant mutants raised against IP 1, 3 and 4 were plated at 5× MIC of each of the respective compounds. A wild-type control demonstrates the resistant nature of the mutants.CC BY · PubMed Central
Figure 5 M. bovis BCG genome region harboring the genes for the cytochrome bc 1 complex and ctaE. The DNA regions cloned into the pMV261 vector are indicated.
Figure 5 M. bovis BCG genome region harboring the genes for the cytochrome bc 1 complex and ctaE. The DNA regions cloned into the pMV261 vector are indicated.CC BY · PubMed Central
Figure 6 Effect on the MIC of IP 3 during the over-expression of QcrB in M. bovis BCG. The over-expression constructs pMV261, pMV261::qcrB, pMV261::qcrCAB and pMV261::ctaE-qcrCAB were electroporated into M. bovis BCG and the MIC of IP 3 was evaluated. The plate lay-out is shown (M. bovis BCG containing the construct detailed) and the MIC of IP 3 with reference to wild-type M. bovis BCG is stated along with the corresponding concentration analyzed. Kanamycin was present at 25 µg/ml to select for the pMV261 vector.
Figure 6 Effect on the MIC of IP 3 during the over-expression of QcrB in M. bovis BCG. The over-expression constructs pMV261, pMV261::qcrB, pMV261::qcrCAB and pMV261::ctaE-qcrCAB were electroporated into M. bovis BCG and the MIC of IP 3 was evaluated. The plate lay-out is shown (M. bovis BCG containing the construct detailed) and the MIC of IP 3 with reference to wild-type M. bovis BCG is stated along with the corresponding concentration analyzed. Kanamycin was present at 25 µg/ml to select for the pMV261 vector.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 180

Metadata

Authors
Abrahams, K. A., Cox, J. A. G., Spivey, V. L., Loman, N. J., Pallen, M. J., Constantinidou, C., Fernández, R., Alemparte, C., Remuiñán, M. J., Barros, D., Ballell, L., & Besra, G. S.
Affiliations
  • University of Birmingham (GB)
  • GlaxoSmithKline (Spain) (ES)
Corresponding author
Besra, Gurdyal S.
Venue
PLoS ONE
Published
2012-12-31
Volume
7
Issue
12
Pages
e52951
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1974074976
Cited by
177
References
53
Citations by year
2026: 3 · 2025: 8 · 2024: 5 · 2023: 12 · 2022: 7 · 2021: 11 · 2020: 18 · 2019: 16 · 2018: 17 · 2017: 16 · 2016: 19 · 2015: 22 · 2014: 20 · 2013: 3
FWCI
10.16
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Aston Publications Explorer (Aston University) (acceptedVersion)
  • Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
Funders
  • University of Warwick
  • European Commission (261378, 2007–2013, FP7 2007-2013)
  • Biotechnology and Biological Sciences Research Council (1112080)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Biological Evaluation
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
imidazo[1,2-a]pyridines, Mycobacterium tuberculosis, Mycobacterium bovis BCG, drug resistance, cross-resistance, gene dosage, lead compound identification, murine tuberculosis model, tuberculosis drug discovery
MeSH terms
Animals, Antitubercular Agents, Dogs, Humans, Microbial Sensitivity Tests, Microsomes, Liver, Mycobacterium bovis, Mycobacterium tuberculosis, Pyridines, Tuberculosis, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.